Precision for All - Capital Markets Webinar
Diaceutics PLC
'Precision for All'
Capital Markets Webinar - Thursday, 5 November 2026
New York, Belfast and London, 14 October 2026 - Diaceutics PLC (AIM: DXRX), a leading technology and solutions provider to the pharma and biotech industry, will host a virtual Capital Markets Event for analysts and investors to discuss 'Precision for All', on Thursday, 5 November 2026 at 1400-1600 GMT (0900-1100 ET).
Entitled 'Precision for All', the webinar will feature presentations from Diaceutics' senior management team and provide investors with a deeper understanding of the market opportunity, the Group's strategic positioning and its ambition to expand access to precision medicine.
No new material trading information will be disclosed and the presentation and recording of the event will be available on the Company's website after the capital markets webinar conclusion - www.diaceutics.com/investors
To register your interest in attending, please use the following link:
https://us06web.zoom.us/webinar/register/WN_bhS2fKduQt66-WsQwn0oAA
Enquiries:
Diaceutics PLC
Ryan Keeling, Chief Executive Officer
Tel: +44 (0)28 9040 6500
Nick Roberts, Chief Financial Officer
investorrelations@diaceutics.com
Canaccord Genuity Limited (Nomad & Broker)
Tel: +44 (0)20 7253 8000
Simon Bridges, Andrew Potts, Harry Rees
About Diaceutics
At Diaceutics, our mission is to redefine commercialization for diagnostic-driven therapies, so every eligible patient is found, diagnosed and receives the right therapy at the right time. Since 2005, we have combined diagnostic intelligence, expert insight and targeted engagement to help biopharma teams see where patients are being missed and close the gaps between testing, treatment decisions and therapy adoption. Today, we work with 21 of the top 30 pharma companies, and the therapies we support touch 1 in 10 American lives. We envision a future where precision is not the privilege of the few, but the standard for all.
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.ENDMSCDZMMGMFNGVZM
